October 9, 2008

QLT Announces the Initiation of a Phase I Trial of Its Synthetic Retinoid Product

VANCOUVER, Oct. 9 /PRNewswire-FirstCall/ -- QLT Inc. (NASDAQ: QLTI; TSX: QLT) announced today that it has initiated a Phase I safety study in healthy adults of QLT091001, an orally administered synthetic retinoid replacement therapy for 11-cis-retinal, which is a key biochemical component of the visual retinoid cycle. The drug is being developed for the potential treatment of Leber's Congenital Amourosis (LCA), an inherited progressive retinal degenerative disease that leads to retinal dysfunction and visual impairment beginning at birth.

The Phase I study is an open-label, single center, ascending dose trial that will determine the safety and tolerance of multiple administrations of the synthetic retinoid drug in approximately 18 healthy adult volunteers. Participants will be enrolled in up to 6 cohorts of increasing doses.

"We believe our retinoid synthetic drug program is a very interesting opportunity as there are no currently available treatments for patients with LCA, which affects one in one-hundred thousand newborns world-wide," said Bob Butchofsky, President and Chief Executive Officer of QLT. "This program also supports the Company's new ocular focus and we look forward to reporting the Phase I data in the first half of 2009. We hope that our findings will support further clinical studies in this orphan indication."

About Synthetic Retinoid Drugs

Genetic diseases in the eye such as Leber's Congenital Amaurosis (LCA) and Retinitis Pigmentosa (RP) arise from gene mutations of enzymes or proteins required in the biochemistry of vision. QLT091001 is a replacement for 11-cis-retinal which is an essential component of the retinoid-rhodopsin cycle and visual function. Two different gene mutations (Retinal pigment epithelium protein 65 (RPE65) and lecithin-retinol acyltransferase (LRAT)) result in an inadequate production of 11-cis-retinal and occur in approximately 10% of patients with LCA and to a lesser extent in RP.

The basis for using synthetic retinoids as replacement therapy for conditions where genetic defects result in deficiency of 11-cis-retinal is founded on experiments in mouse genetic models. These experiments used mice that have mutations in either the RPE65 or LRAT genes, the same as those associated with LCA in humans. Both mouse models have clinical features of the human disease. The biological activity of the synthetic retinoid was monitored by measuring the level of pigment-related compounds in the eye. Retinal function was also assessed by detecting electroretinograms (ERGs), electrical nerve signals from the retina. Oral administration of QLT091001 showed evidence of having corrected the biochemical defect in the retinoid cycle in light-sensing cells (rods) and appeared to restore ERG responses to light in both models of LCA.

About Leber's Congenital Amaurosis

Leber Congenital Amaurosis (LCA) is an inherited degenerative retinal disease characterized by abnormalities such as roving eye movements and sensitivity to light, and manifesting in severe vision loss from birth. Eye examinations of infants with LCA reveal normal appearing retinas. However, low level of retinal activity, measured by electroretinography (ERG), indicates very little visual function.

About QLT

QLT Inc. is a global biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies. Our research and development efforts are focused on pharmaceutical products in the fields of ophthalmology and dermatology. In addition, we utilize three unique technology platforms, photodynamic therapy, Atrigel(R) and punctal plugs with drugs, to create products such as Visudyne(R) and Eligard(R) and future product opportunities. For more information, visit our web site at http://www.qltinc.com/.

In April of 2006, QLT entered into an exclusive worldwide co-development and licensing agreement with Retinagenix, LLC, to develop active synthetic retinoid products for the treatment of degenerative retinal diseases. Pre-clinical studies have demonstrated that orally administered synthetic retinoid drugs cause long-lasting restoration of retinal function. Under the terms of the agreement, QLT is responsible to develop and commercialize the products for use in ocular and all other human diseases. Retinagenix has participated in research in support of the co-development collaboration and is eligible to receive payments upon achievement of certain development, approval and sales milestones as well as a single digit royalty on net sales.

   QLT Plug Delivery, Inc. is a wholly-owned subsidiary of QLT Inc.   Atrigel is a registered trademark of QLT USA, Inc.   Visudyne is a registered trademark of Novartis AG.   Eligard is a registered trademark of Sanofi-aventis.   

QLT Inc. is listed on The NASDAQ Stock Market under the trading symbol "QLTI" and on The Toronto Stock Exchange under the trading symbol "QLT."

Certain statements contained in this press release, which are not historical facts, are "forward-looking statements," of QLT within the meaning of the Private Securities Litigation Reform Act of 1995 and constitute "forward-looking information" within the meaning of applicable Canadian securities laws. Such statements include, but are not limited to: our beliefs regarding the potential benefits, targets, market opportunity and commercial success of our synthetic retinoid drug; our expectations regarding our clinical development plans and strategy for the technology and timelines associated with these; and statements which contain language such as "expects,""will", "plans,""estimates,""intends,""believes" and similar expressions that do not relate to historical matters. Forward-looking statements are predictions only which involve known and unknown risks, uncertainties and other factors that may cause our actual results to be materially different from the results expressed or implied by such statements. Many such risks, uncertainties and other factors are taken into account as part of our assumptions underlying these forward-looking statements and include, among others, the following: risks and uncertainties associated with the timing, expense and outcome of research and development programs and commercialization of products (including the difficulty of predicting the timing and outcome of the synthetic retinoid drug development efforts, clinical testing and regulatory approvals or actions); uncertainties regarding the impact of competitive products and pricing; risks and uncertainties associated with the safety and effectiveness of our technology; risks and uncertainties related to the scope, validity, and enforceability of our intellectual property rights and the impact of patents and other intellectual property of third parties; and other factors as described in detail in QLT's Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and other filings with the U.S. Securities and Exchange Commission and Canadian securities regulatory authorities. Forward-looking statements are based on the current expectations of QLT and QLT does not assume any obligation to update such information to reflect later events or developments except as required by law.

   List of references:    Batten ML, Imanishi Y, Tu DC, et al. Pharmacological and rAAV gene   therapy rescue of visual functions in a blind mouse model of Leber   congenital amaurosis. PLoS Medicine. 2005;2(11):1177-1189.    Van Hooser JP, Liang Y, Maeda T, et al. Recovery of visual functions in a   mouse model of Leber congenital amaurosis. J Biol Chem.   2002;277(21):19173-19182.    Van Hooser JP, Aleman TS, He Y-G, et al. Rapid restoration of visual   pigment and function with oral retinoid in a mouse model of childhood   blindness. Proc Natl Acad Sci USA. 2000;97(15):8623-8628.    Travis GH, Golczak M, Moise AR, and Palczewski K. Diseases caused by   defects in the Visual Cycle: Retinoids as Potential Therapeutic Agents.   Annu. Rev. Pharmocol. Toxicol. 2007;47: 469-512  

QLT Inc.

CONTACT: QLT Inc. Media Contact: Vancouver, Canada, Karen Peterson,Telephone: (604) 707-7000 or 1-800-663-5486, Fax: (604) 707-7001; The TroutGroup Investor Relations Contact: New York, USA, Christine Yang, Telephone:(646) 378-2929 or Marcy Strickler Telephone: (646) 378-2927